Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00151281 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00151281 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 25 participants.
The verdict
NCT00151281, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be assessed. Secondary Objectives: 1. Assess the toxicity profiles of RT-PEPC treatment in patients with relapsed mantle cell lymphoma. 2. Prospectively characterize the angiogenic profile of patients with mantle cell lymphoma during treatment with RT-PEPC. The dynamics of the angiogenic profile will be correlated with clinical response to RT-PEPC therapy. 3. Assess the quality of life of patients receiving RT-PEPC treatment
Interventions
- DRUG Rituximab
- DRUG Thalidomide
- DRUG PEPC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-11 |
| Est. Completion | 2011-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00151281
The ClinicalTrials.gov registry entry for NCT00151281 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT00151281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00151281 about?
NCT00151281 is a clinical study titled "Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma". Primary Objective: Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide, and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be ass...
What is the current status of trial NCT00151281?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2004-11. Estimated completion is 2011-04-07.
What interventions are being tested in trial NCT00151281?
The interventions under investigation include: Rituximab (DRUG), Thalidomide (DRUG), PEPC (DRUG).
Who is sponsoring clinical trial NCT00151281?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.